Skip to content

NASDAQ · small · thesis board

CAPR Capricor Therapeutics

Cardiosphere-derived cell therapy for DMD cardiomyopathy

View race

Thesis

Editorial summary — not a primary filing

Cell therapy deramiocel is under FDA review for DMD cardiomyopathy; outcome hinges on efficacy package and manufacturing readiness.

Next gate

2026-08-22ConfirmedPDUFA

PDUFA — deramiocel DMD

9 days · FDA: FDA / company PDUFA disclosure

Survive-to-Event

ok

Cash covers the next gate with ~16 months spare (curated estimate).

Unverified estimate — not from a live SEC parse

Cash runway (~500d)100%
Days to gate (9d)2%
Show math

$148M cash ÷ $9M/mo burn ≈ 500 days. Source: curated SEC quarter figures.

Cash $148M as of 2026-03-31 (SEC)

Pipeline spine

  1. Preclinical
  2. Ph1
  3. Ph2
  4. Ph3
  5. Filed
  6. Approved

Rivals in this race

Open race →
SRPTApprovedokRCKTPh2okSLDBPh1ok

Risks

  • Regulatory: PDUFA outcome uncertain
  • Clinical: single-indication concentration
  • Dilution: may raise if label delayed
  • Competitive: gene therapy standards evolving

Source trail

  1. SECCash from latest reported quarter (curated)as of 2026-03-31
  2. ClinicalTrials.govNCT05126758as of 2026-07-01
  3. CompanyIR / press disclosuresas of 2026-07-01